Novel cilengitide-based cyclic RGD peptides as αvβ3 integrin inhibitors

[Display omitted] In this letter, we report a series of five new RGD-containing cyclic peptides as potent inhibitors to αvβ3 integrin protein. We have incorporated various unnatural lipophilic amino acids into the cyclic RGD framework of cilengitide, which is selective for αvβ3 integrin. All the new...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry letters 2020-04, Vol.30 (8), Article 127039
Main Authors: Meena, Chhuttan L., Singh, Dharmendra, Weinmüller, Michael, Reichart, Florian, Dangi, Abha, Marelli, Udaya Kiran, Zahler, Stefan, Sanjayan, Gangadhar J.
Format: Article
Language:English
Subjects:
Anticancer drugs
Cilengitide
Integrins
RGD cyclicpeptides
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] In this letter, we report a series of five new RGD-containing cyclic peptides as potent inhibitors to αvβ3 integrin protein. We have incorporated various unnatural lipophilic amino acids into the cyclic RGD framework of cilengitide, which is selective for αvβ3 integrin. All the newly synthesized cyclic peptides were evaluated in vitrosolid phase binding assay and investigated for their bindingbehaviourtowards integrin subtypes. All the cyclic peptides were synthesized in excellent yield following solution-phase coupling strategy. The cyclic RGD peptides 1a-e exhibited IC50 of 9.9, 5.5, 72, 11 and 3.3 nM, respectively, towardsαvβ3 integrin protein. This finding offers further opportunities for the introduction unusual amino acids into the cyclic peptide framework of cilengitide.
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2020.127039